VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
Recruiting
National Cancer Institute (NCI)
Phase 1
2017-09-15
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human
interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib
phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that
has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted
ability to spread to tumor cells and not to healthy cells. It also contains a gene for a
protein, NIS, which helps the body concentrate iodine making it possible to track where the
virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells.
Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in
treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
Recruiting
Mayo Clinic
Phase 1
2017-09-15
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human
interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib
phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that
has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted
ability to spread to tumor cells and not to healthy cells. It also contains a gene for a
protein, NIS, which helps the body concentrate iodine making it possible to track where the
virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells.
Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in
treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
